Zobrazeno 1 - 10
of 54
pro vyhledávání: ''
Autor:
P. Osterlund, S. Kinos, P. Pfeiffer, T. Salminen, J.J.M. Kwakman, J.-E. Frödin, C.H. Shah, H. Sorbye, R. Ristamäki, P. Halonen, L.M. Soveri, E. Heervä, A. Ålgars, M. Bärlund, H. Hagman, R. McDermott, M. O’Reilly, R. Röckert, G. Liposits, R. Kallio, P. Flygare, A.J. Teske, E. van Werkhoven, C.J.A. Punt, B. Glimelius
Publikováno v:
ESMO open, 7(3):100427. Elsevier BV
ESMO Open
ESMO Open
Publisher Copyright: © 2022 The Author(s) Background: Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity. S-1 is a fluoropyrimidine with low rates of cardiotoxicity,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a13f97b5f1a9aa6049448c1fbbc3f020
http://urn.fi/urn:nbn:fi-fe2023071190533
http://urn.fi/urn:nbn:fi-fe2023071190533
Autor:
Adi Mory, Tamar Paperna, Gili Reznick-Levi, Alan R. Shuldiner, Claudia Gonzaga-Jauregui, Miora Feinstien, Lina Basel-Salmon, Nivin Moustafa, Hagit Baris Feldman, Alina Kurolap, Yael Goldberg, Nitzan Sharon-Shwartzman, Elizabeth E. Half, Yishai Ofran, Yariv Carasso
Publikováno v:
Journal of Medical Genetics. 57:500-504
BackgroundChromosomal instability, as reflected by structural or copy-number changes, is a known cancer characteristic but are rarely observed in healthy tissue. Mutations in DNA repair genes disrupt the maintenance of DNA integrity and predispose to
Autor:
Qi Mei, Guangyuan Hu, Yang Yang, Bo Liu, Junping Yin, Ming Li, Qiao Huang, Xi Tang, Alexander Böhner, Amy Bryant, Christian Kurts, Xianglin Yuan, Jian Li
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e004157
Anti-COVID-19 vaccination may have functional implications for immune checkpoint inhibitor treatment in patients with cancer. This study was undertaken to determine whether the safety or efficacy of anti-PD-1 therapy is reduced in patients with cance
Autor:
Dettorre, Gino M., Dolly, Saoirse, Loizidou, Angela, Chester, John, Jackson, Amanda, Mukherjee, Uma, Zambelli, Alberto, Aguilar Company, Juan, Bower, Mark, Sng, Christopher C. T., Salazar Soler, Ramón, Bertuzzi, Alexia, Brunet, Joan, Mesia, Ricard, Sita-Lumsden, Ailsa, Seguí, Elia, Biello, Federica, Generali, Daniele, Grisanti, Salvatore, Seeva, Pavetha, Rizzo, Gianpiero, Libertini, Michela, Maconi, Antonio, Moss, Charlotte, Russell, Beth, Harbeck, Nadia, Vincenzi, Bruno, Bertulli, Rossella, Ottaviani, Diego, Liñan, Raquel, Marrari, Andrea, Carmona García, M. Carmen, Chopra, Neha, Tondini, Carlo Alberto, Mirallas, Oriol, Tovazzi, Valeria, Fotia, Vittoria, Cruz, Claudia Andrea, Saoudi González, Nadia, Felip, Eudald, Roqué, Ariadna, Lee, Alvin J. X., Newsom-Davis, Tom, García Illescas, David, Reyes, Roxana, Wong, Yien Ning Sophia, Ferrante, Daniela, Scotti, Lorenza, Marco Hernández, Javier, Ruiz Camps, Isabel, Patriarca, Andrea, Rimassa, Lorenza, Chiudinelli, Lorenzo, Franchi, Michela, Santoro, Armando, Prat Aparicio, Aleix, Gennari, Alessandra, Van Hemelrijck, Mieke, Tabernero Caturla, Josep, Diamantis, Nikolaos, Pinato, David J., OnCovid study group
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Scientia
Universidad de Barcelona
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Scientia
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Inflamació; Mediadors d'inflamació Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Inflamación; Mediadores de la inflamación Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Inflammation; Inflammation mediato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38b479d72020cc81746269413907119b
http://hdl.handle.net/2445/176045
http://hdl.handle.net/2445/176045
Autor:
Rebecca Kristeleit, Antoine Italiano, Hendrik Tobias Arkenau, Mika Mustonen, Pasi Hakulinen, Analia Azaro, Giuseppe Curigliano, Petri Bono, Jordi Rodon, Tarja Ikonen, Ulrik Lassen, Chris Garratt, Christophe Massard, Katriina Peltola
Publikováno v:
Scientia
ESMO Open, Vol 5, Iss 6 (2020)
ESMO Open
Bono, P, Massard, C, Peltola, K J, Azaro, A, Italiano, A, Kristeleit, R S, Curigliano, G, Lassen, U, Arkenau, H T, Hakulinen, P, Garratt, C, Ikonen, T, Mustonen, M V J & Rodon, J A 2020, ' Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours ', ESMO Open, vol. 5, no. 6, e001081 . https://doi.org/10.1136/esmoopen-2020-001081
ESMO Open, Vol 5, Iss 6 (2020)
ESMO Open
Bono, P, Massard, C, Peltola, K J, Azaro, A, Italiano, A, Kristeleit, R S, Curigliano, G, Lassen, U, Arkenau, H T, Hakulinen, P, Garratt, C, Ikonen, T, Mustonen, M V J & Rodon, J A 2020, ' Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours ', ESMO Open, vol. 5, no. 6, e001081 . https://doi.org/10.1136/esmoopen-2020-001081
Estudi d'escalada de dosis; Fase I; Tumors sòlids Estudio de escalada de dosis; Fase I; Tumores sólidos Dose escalation study; Phase I; Solid tumours Background Genetic alterations in fibroblast growth factor receptor (FGFR) and vascular endothelia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::164c723e495210e45a1eff22d3221919
https://hdl.handle.net/11351/6423
https://hdl.handle.net/11351/6423
Autor:
Jung Ho Kim, Mi-Kyoung Seo, Ji Ae Lee, Seung-Yeon Yoo, Hyeon Jeong Oh, Hyundeok Kang, Nam-Yun Cho, Jeong Mo Bae, Gyeong Hoon Kang, Sangwoo Kim
Publikováno v:
Journal for Immunotherapy of Cancer
BackgroundColorectal cancers (CRCs) with microsatellite instability-high (MSI-H) are hypermutated tumors and are generally regarded as immunogenic. However, their heterogeneous immune responses and underlying molecular characteristics remain largely
Autor:
Hamzah Abu-Sbeih, Lauren Nicholas Herrera, Mehmet Altan, Pablo C. Okhuysen, Yinghong Wang, Anne Marie Chaftari, Robert R. Jenq, Tenglong Tang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-1 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
The gut microbiome impacts the efficacy of immune checkpoint inhibitor (ICI) therapy and the development of ICI-mediated diarrhea and/or colitis (IMDC). Antibiotic therapy,especially that with anaerobic activity, has profound effects on the gut micro
Autor:
Noha Abdel-Wahab, Michael A. Davies, Karin Woodman, Sudhakar Tummala, Heather Lin, Maria E. Suarez-Almazor, Houssein Safa, Adi Diab, Faisal Fa’ak, Theresa E Rodgers, Cassian Yee, Van Anh Trinh, Daniel H. Johnson, Chantal Saberian
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Myasthenia gravis (MG) is a rare but life-threatening adverse event of immune checkpoint inhibitors (ICI). Given the limited evidence, data from a large cohort of patients is needed to aid in recognition and management of this fatal compli
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Background Programmed cell death 1 inhibitors have revolutionized therapy for cancer by their outstanding effectiveness. However, they may cause adverse effects, among which inflammatory myopathy is one of the most disabling. To elucidate its mechani
Autor:
Christopher R. Heery, Julie Collins, Marijo Bilusic, Claudia Palena, James L. Gulley, Jeffrey Schlom, Ravi A. Madan, Margaret E. Gatti-Mays, Jennifer L. Marte, Renee N. Donahue, Julius Strauss, Fatima Karzai
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a chemokine that promotes tumor progression, immune escape, epithelial-mesenchymal transition, and recruitment of myeloid-d